|
|
||
|
|||
|
|
|
|
    |
|||
 |
|
||
| Recent press releases
|
24 July 2007 Lectus Therapeutics strengthens management team and SAB Enhancement of the management team and Scientific Advisory Board positions the company to effectively execute its Research & Development agenda Cambridge, UK, 24 July 2007: Lectus Therapeutics Ltd, the drug discovery and development company focusing on next-generation ion channel modulators, announced today that it had appointed to its management team Dr Peter Buchan as Chief Scientific Officer and Dr Richard Armer as Research Director. Dr Peter Buchan brings more than 30 years experience of both preclinical and early clinical development working across a broad range of therapeutic areas. Peter recently held a number of positions at Pharmacia (later Pfizer, then Nerviano Medical Sciences), most recently Director of Clinical Pharmacology. He will be responsible for the development agenda for the company’s portfolio of next-generation ion channel modulators. Dr Richard Armer’s appointment follows the retirement of Lectus’s current Research Director, Dr Geoff Lawton. Richard joins Lectus from Oxagen Limited, where he held the position of Director of Chemistry. He will be responsible for advancing the company’s research agenda. His appointment follows the opening of the company’s second Cambridge (UK) research facility, located at the Peterhouse Technology Park, which houses the company’s medicinal chemistry laboratories. Dr Geoff Lawton, the company’s former Research Director will continue to work closely with the company on its novel next-generation ion channel therapeutics, following his appointment to the company’s Scientific Advisory Board. Dr Roland Kozlowski, CEO of Lectus, commented: “Recruitment of these high calibre individuals to the management team and scientific advisory board will enable the business to transition effectively from a research organisation to a company executing both research and development. By bringing chemistry in house, through the development of our new facility, we can ensure that the company fully exploits the competitive advantage associated with our next-generation ion channel therapeutics.”
|
|||
 |
|
|
|
| © Lectus Therapeutics Ltd. 2003–2010 Registered Offices: 123 Deansgate Manchester M3 2BU |
|
|
|
